NICE backs Lilly's Taltz for psoriasis

1 November 2016

UK medicines cost effectiveness watchdog the National Institute for Health and Care excellence (NICE) has today published draft guidance for US pharma major Eli Lilly’s (NYSE: LLY) (ixekizumab) for psoriasis.

The NICE recommends ixekizumab as an option for treating plaque psoriasis in adults, only if:

the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10;
the disease has not responded to standard systemic therapies (for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or the person cannot have the treatment or it is not tolerated and;
the company provides ixekizumab with the discount agreed in the patient access scheme; and
treatment is stopped at 12 weeks if psoriasis has not responded adequately. An adequate response is defined as a 75% reduction in the PASI score from when treatment started.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK